Correlation Between Scandinavian ChemoTech and Vitrolife

Can any of the company-specific risk be diversified away by investing in both Scandinavian ChemoTech and Vitrolife at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Scandinavian ChemoTech and Vitrolife into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Scandinavian ChemoTech AB and Vitrolife AB, you can compare the effects of market volatilities on Scandinavian ChemoTech and Vitrolife and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Scandinavian ChemoTech with a short position of Vitrolife. Check out your portfolio center. Please also check ongoing floating volatility patterns of Scandinavian ChemoTech and Vitrolife.

Diversification Opportunities for Scandinavian ChemoTech and Vitrolife

0.8

Correlation Coefficient

Scandinavian ChemoTech  Vitrolife

Very poor diversification

The 3 months correlation between Scandinavian and Vitrolife is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Scandinavian ChemoTech AB and Vitrolife AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vitrolife AB and Scandinavian ChemoTech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Scandinavian ChemoTech AB are associated (or correlated) with Vitrolife. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vitrolife AB has no effect on the direction of Scandinavian ChemoTech i.e., Scandinavian ChemoTech and Vitrolife go up and down completely randomly.

Pair Corralation between Scandinavian ChemoTech and Vitrolife

Assuming the 90 days trading horizon Scandinavian ChemoTech AB is expected to under-perform the Vitrolife. In addition to that, Scandinavian ChemoTech is 2.3 times more volatile than Vitrolife AB. It trades about -0.06 of its total potential returns per unit of risk. Vitrolife AB is currently generating about -0.09 per unit of volatility. If you would invest  23,860  in Vitrolife AB on October 11, 2024 and sell it today you would lose (2,720) from holding Vitrolife AB or give up 11.4% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Scandinavian ChemoTech AB  vs.  Vitrolife AB

Scandinavian ChemoTech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Scandinavian ChemoTech AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Vitrolife AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Vitrolife AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Scandinavian ChemoTech and Vitrolife

The main advantage of trading using opposite Scandinavian ChemoTech and Vitrolife positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Scandinavian ChemoTech position performs unexpectedly, Vitrolife can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vitrolife will offset losses from the drop in Vitrolife's long position.

The idea behind Scandinavian ChemoTech AB and Vitrolife AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.